| Brady Bach, PLMHP, PLADC | |
|
2912 Bar Harbor Dr, Bellevue, NE 68123-2772 | |
| (402) 619-0760 | |
| Not Available |
| Full Name | Brady Bach |
|---|---|
| Gender | Male |
| Speciality | Counselor - Mental Health |
| Location | 2912 Bar Harbor Dr, Bellevue, Nebraska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871355685 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Brady Bach, PLMHP, PLADC 2912 Bar Harbor Dr, Bellevue, NE 68123-2772 Ph: (402) 619-0760 | Brady Bach, PLMHP, PLADC 2912 Bar Harbor Dr, Bellevue, NE 68123-2772 Ph: (402) 619-0760 |
News Archive
Every parent wants to give their child the best start in life, but what if that consideration needed to happen before the baby was even born?
The coronavirus pandemic has sparked a sense of urgency as it actively spreads across the globe. The number of reported cases has now surpassed 8.46 million people, with a death toll of more than 453,000. Scientists and pharmaceutical companies are racing to develop an effective treatment and vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Working with an international consortium conducting research on breast, ovarian and prostate cancer among 200,000 people, Professor Jacques Simard, holder of the Canada Research Chair in Oncogenetics at Laval University, was actively involved in the discovery of DNA "spelling mistakes" linked to breast cancer.
Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded a proof of concept contract by the U.S. Army Research, Development and Engineering Command laboratory specifically the Edgewood Chemical Biological Center ("ECBC") Research & Technology Directorate.
KemPharm, Inc. today announced positive results from a Phase 1 clinical trial of KP106, its novel prodrug for attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of the active pharmaceutical compound d-amphetamine and a ligand, was created using KemPharm's proprietary Ligand Activated Therapy (LAT) prodrug approach.
› Verified 3 days ago
Katherine Kimmerling, LIMHP, LADC Counselor Medicare: Not Enrolled in Medicare Practice Location: 730 Fort Crook Rd N, Bellevue, NE 68005 Phone: 402-292-9105 Fax: 402-292-0342 | |
Mrs. Alyson Nichole Carter, LIMHP, PLADC,CPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 608 W 29th Ave, Bellevue, NE 68005 Phone: 419-203-3620 | |
Veronica Villa, PLADC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1103 Galvin Rd S Ste L 1/2, Bellevue, NE 68005 Phone: 402-213-1655 | |
Jessica Fuller, PLMHP Counselor Medicare: Medicare Enrolled Practice Location: 11515 S 39th St, Bellevue, NE 68123 Phone: 402-292-9105 Fax: 402-292-0342 | |
Nandi Nzingha Naomi Thomas, PLADC Counselor Medicare: Not Enrolled in Medicare Practice Location: 112 E Mission Ave, Bellevue, NE 68005 Phone: 402-257-1122 | |
Catherine Jo Howard, LMHP LCSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 1309 Harlan Dr Ste 102, Bellevue, NE 68005 Phone: 402-850-0151 | |
Nina Wilson, LMHP Counselor Medicare: Not Enrolled in Medicare Practice Location: 1406 Fort Crook Rd S, 401, Bellevue, NE 68005 Phone: 402-661-9102 |